Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy
Authors:
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 157, 103096
Abstract
No abstract availableKeywords
This publication has 148 references indexed in Scilit:
- EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen LossClinical Cancer Research, 2014
- A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19Immunological Reviews, 2013
- Regulation and function of mTOR signalling in T cell fate decisionsNature Reviews Immunology, 2012
- Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage MalignanciesCancer Research, 2011
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significanceBlood, 2009
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsJournal of Experimental Medicine, 2005
- Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapyTrends in Immunology, 2005
- Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T LymphocytesCancer Research, 2004
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences, 1993